IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES
AssigneePictor Limited
InventorsSandeep Kumar Vashist, Lionel Gilles Guiffo Djoko, Bhavesh Govind, Richard Janeczko
Life of this patent
Estimating the term…
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.
Claims38
A substrate comprising at least two capture elements specific for SARS-CoV-2 on the substrate, each capture element corresponding to and being able to bind a target analyte, the substrate further optionally comprising a plurality of control elements comprising:
- a) at least one fiduciary marker, b) at least one negative control to monitor background signal, c) at least one negative control to monitor assay specificity, d) at least one positive colorimetric control, e) at least one positive control to monitor assay performance and any combination thereof.
The method of claim 27, wherein the blood sample is serum or plasma.
Dependencies are inferred from the claim text.